- Home
- ACAD vs XENE Comparison
ACAD vs XENE Comparison
Compare ACAD & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACAD | XENE |
|---|---|---|
| Founded | 1993 | 1996 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.2B |
| IPO Year | 2000 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ACAD | XENE |
|---|---|---|
| Price | $22.54 | $58.46 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 22 | 12 |
| Target Price | $30.55 | ★ $67.17 |
| AVG Volume (30 Days) | ★ 1.7M | 1.4M |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 69.12 | N/A |
| EPS | ★ 2.30 | N/A |
| Revenue | ★ $726,437,000.00 | $311,000.00 |
| Revenue This Year | $18.90 | N/A |
| Revenue Next Year | $11.62 | $2,436.26 |
| P/E Ratio | $9.82 | ★ N/A |
| Revenue Growth | ★ 40.45 | N/A |
| 52 Week Low | $14.08 | $28.19 |
| 52 Week High | $28.35 | $62.91 |
Technical Indicators
Market Signals| Indicator | ACAD | XENE |
|---|---|---|
| Relative Strength Index (RSI) | 53.66 | 65.49 |
| Support Level | $19.87 | $39.93 |
| Resistance Level | $23.06 | $59.44 |
| Average True Range (ATR) | 0.67 | 1.94 |
| MACD | 0.26 | -0.17 |
| Stochastic Oscillator | 85.97 | 86.21 |
Price Performance
Historical ComparisonAbout ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About XENE Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.